Inhibition of HIV infection by structural proteins of the inner nuclear membrane is associated with reduced chromatin dynamics.


Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
28 09 2021
Historique:
received: 15 01 2021
revised: 21 07 2021
accepted: 03 09 2021
entrez: 30 9 2021
pubmed: 1 10 2021
medline: 11 2 2022
Statut: ppublish

Résumé

The human immunodeficiency virus (HIV) enters the nucleus to establish infection, but the role of nuclear envelope proteins in this process is incompletely understood. Inner nuclear transmembrane proteins SUN1 and SUN2 connect nuclear lamins to the cytoskeleton and participate in the DNA damage response (DDR). Increased levels of SUN1 or SUN2 potently restrict HIV infection through an unresolved mechanism. Here, we find that the antiviral activities of SUN1 and SUN2 are distinct. HIV-1 and HIV-2 are preferentially inhibited by SUN1 and SUN2, respectively. We identify DNA damage inducers that stimulate HIV-1 infection and show that SUN1, but not SUN2, neutralizes this effect. Finally, we show that chromatin movements and nuclear rotations are associated with the effects of SUN proteins and Lamin A/C on infection. These results reveal an emerging role of chromatin dynamics and the DDR in the control of HIV infection by structural components of the nuclear envelope.

Identifiants

pubmed: 34592156
pii: S2211-1247(21)01217-1
doi: 10.1016/j.celrep.2021.109763
pii:
doi:

Substances chimiques

Chromatin 0
Intracellular Signaling Peptides and Proteins 0
Membrane Proteins 0
Microtubule-Associated Proteins 0
Nuclear Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109763

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Anvita Bhargava (A)

Institut Curie, PSL Research University, INSERM U932, Paris, France.

Alice Williart (A)

Institut Curie, PSL Research University, CNRS UMR144, Paris, France.

Mathieu Maurin (M)

Institut Curie, PSL Research University, INSERM U932, Paris, France.

Patricia M Davidson (PM)

Laboratoire Physico-Chimie Curie, Institut Curie, CNRS UMR168, Sorbonne Université, PSL Research University, Paris, France.

Mabel Jouve (M)

Institut Curie, UMR3215, Paris, France.

Matthieu Piel (M)

Institut Curie, PSL Research University, CNRS UMR144, Paris, France.

Xavier Lahaye (X)

Institut Curie, PSL Research University, INSERM U932, Paris, France.

Nicolas Manel (N)

Institut Curie, PSL Research University, INSERM U932, Paris, France. Electronic address: nicolas.manel@curie.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH